IMAC Holdings, Inc. (BACK)
OTCMKTS · Delayed Price · Currency is USD
0.0720
+0.0040 (5.88%)
Oct 26, 2025, 8:00 PM EDT
IMAC Holdings Revenue
IMAC Holdings had revenue of $57.80K in the twelve months ending June 30, 2025, up 266.98% year-over-year. In the year 2024, IMAC Holdings had annual revenue of $72.05K.
Revenue (ttm)
57.80K
Revenue Growth
+266.98%
P/S Ratio
4.71
Revenue / Employee
3.85K
Employees
15
Market Cap
272.52K
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 72.05K | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | 14.39M | 1.55M | 12.08% |
| Dec 31, 2020 | 12.84M | -2.29M | -15.14% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| American Oncology Network | 1.76B |
| Veradigm | 588.02M |
| Jushi Holdings | 256.36M |
| Glass House Brands | 221.55M |
| Elite Pharmaceuticals | 105.45M |
| Silence Therapeutics | 27.17M |
| Nuo Therapeutics | 1.95M |
| Northwest Biotherapeutics | 1.09M |
IMAC Holdings News
- 6 weeks ago - Ignite Proteomics Announces Collaboration with Inova Health on a Biomarker Study for Late-Stage Cancers - GlobeNewsWire
- 2 months ago - IMAC Holdings Announces Research Collaboration with Vanderbilt University Medical Center to Advance Immuno-Oncology Biomarker Discovery - GlobeNewsWire
- 8 months ago - Ignite Proteomics to Present Data on MHC-II as a Predictor of Pembrolizumab Response at NCCN Annual Conference - GlobeNewsWire
- 8 months ago - Ignite Proteomics Completes Acquisition of PLA Code 0249U for Its Advanced Proteomic Breast Cancer Assay - GlobeNewsWire
- 9 months ago - Ignite Proteomics Announces Publication of Study Demonstrating Superiority of Protein Activation Analysis in Predicting Breast Cancer Therapy Response - GlobeNewsWire
- 9 months ago - IMAC Holdings Introduces Ignite Proteomics: A New Standard for Matching Patients with the Right Cancer Therapies - GlobeNewsWire
- 1 year ago - IMAC Holdings receives notification of deficiency from Nasdaq related to delayed filing of quarterly report on Form 10-Q - GlobeNewsWire
- 1 year ago - IMAC Holdings Granted Extension by Nasdaq to Regain Compliance with Listing Rule 5250(c)(1) - GlobeNewsWire